In search of vaccinology’s Holy Grail: developing a pan-sarbecovirus vaccine
Vaccine Insights 2022; 1(1), 95–100
A leading researcher in emerging infectious diseases, Linfa Wang was on a work trip to Wuhan in January 2020 and witnessed the early days of the COVID-19 pandemic firsthand. Back in his lab at Duke-NUS Medical School, Singapore, he set to work developing a new assay that makes it easier to detect neutralizing antibodies for SARS-CoV-2 and other sarbecoviruses. Now, Wang and his team are developing a pan-sarbecovirus vaccine – with help from survivors of the 2003 SARS outbreak.